Proton therapy reduces radiation to nontargeted tissues, but for men with localized prostate cancer that may not translate to better outcomes, according to early results from the large prospective ...
SBRT is not superior to IMRT for DFS at 3 years, but it is safe and might permit better bowel quality of life. In men with favorable intermediate-risk prostate cancer, modest-dose stereotactic body ...
About the Study: In this randomized clinical trial of 698 patients with localized intermediate-risk prostate cancer, stereotactic body radiotherapy was not superior to moderately hypofractionated IMRT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
